2025-03-28 00:52:45
Latest Post
Verso Altima India Pvt Ltd wins order worth Rs. 1 crore from DTDC Express Ltd
BEL receives orders worth Rs.1,385 Crore
IndiGo BluChip: Redefining Airline Loyalty with Unparalleled Benefits and Exclusive Rewards
Luminous partners with SBI to Expand Solar Financing in India
Shriram Finance Limited Secures 'Outstanding' ESG Impact Rating from ICRA ESG
Stock Report
RPG Life Sciences Ltd Q3 FY2025 PAT surges to Rs. 34.93 crores
Posted On : 2025-01-27 21:02:22( TIMEZONE : IST )
RPG Life Sciences Limited has reported Standalone financial results for the period ended December 31, 2024.
Financial Results (Q3 FY2025) - QoQ Comparison
The company has reported total income of Rs. 176.02 crores during the period ended December 31, 2024 as compared to Rs. 174.15 crores during the period ended September 30, 2024.
The company has posted net profit / (loss) of Rs. 34.93 crores for the period ended December 31, 2024 as against net profit / (loss) of Rs. 4.20 crores for the period ended September 30, 2024.
The company has reported EPS of Rs. 21.12 for the period ended December 31, 2024 as compared to Rs. 2.54 for the period ended September 30, 2024.
| Financials | Q3 FY2025 | Q2 FY2025 | % Change |
| Total Income | ₹ 176.02 crs | ₹174.15 crs |  1.07% |
| Net Profit | ₹34.93 crs | ₹4.20 crs | 731.67% |
| EPS | ₹21.12 | ₹2.54 | 731.50% |
Financial Results (Q3 FY2025) - YoY Comparison
The company has reported total income of Rs. 176.02 crores during the period ended December 31, 2024 as compared to Rs.155.62 crores during the period ended December 31, 2023.
The company has posted net profit / (loss) of Rs.34.93 crores for the period ended December 31, 2024 as against net profit / (loss) of Rs.26.46 crores for the period ended December 31, 2023.
The company has reported EPS of Rs.21.12 for the period ended December 31, 2024 as compared to Rs.16 for the period ended December 31, 2023.
| Financials | Q3 FY2025 | Q3 FY2024 | % Change |
| Total Income | ₹ 176.02 crs | ₹155.62 crs | 13.11% |
| Net Profit | ₹34.93 crs | ₹26.46 crs | 32.01% |
| EPS | ₹21.12 | ₹16 | 32.00% |
Financial Results (9 Months Ended FY2025) - YoY Comparison
The company has reported total income of Rs.517.96 crores during the 9 Months period ended December 31, 2024 as compared to Rs.460.62 crores during the 9 Months period ended December 31, 2023.
The company has posted net profit / (loss) of Rs.65.89 crores for the 9 Months period ended December 31, 2024 as against net profit / (loss) of Rs.74.42 crores for the 9 Months period ended December 31, 2023.
The company has reported EPS of Rs.39.84 for the 9 Months period ended December 31, 2024 as compared to Rs.45 for the 9 Months period ended December 31, 2023.
| Financials | 9 Months Ended FY2025 | 9 Months Ended FY2024 | % Change |
| Total Income | ₹517.96 crs | ₹460.62 crs | 12.45% |
| Net Profit | ₹65.89 crs | ₹74.42 crs |  -11.46% |
| EPS | ₹39.84 | ₹45 | -11.47% |
Shares of RPG Life Sciences Limited was last trading in BSE at Rs. 2077.40 as compared to the previous close of Rs. 2166.65. The total number of shares traded during the day was 927 in over 369 trades.
The stock hit an intraday high of Rs. 2159.30 and intraday low of 2066.20. The net turnover during the day was Rs. 1939822.00.
